

May 11, 2026

Consolidated Financial Results for the Nine Months Ended March 31, 2026 (Under Japanese GAAP)

Company name: KOA SHOJI HOLDINGS CO.,LTD.
 Listing: Tokyo Stock Exchange
 Securities code: 9273
 URL: <https://www.koashoji-hd.com/>
 Representative: Toshiyuki SHUTO, President and Representative Director
 Inquiries: Miyoko KOMATSU, Managing Director in charge of Finance & Accounting
 Telephone: +81-45-560-6607
 Scheduled date to commence dividend payments: -
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended March 31, 2026 (from July 1, 2025 to March 31, 2026)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended								
March 31, 2026	18,334	4.0	4,580	4.5	4,551	3.0	3,052	3.1
March 31, 2025	17,620	5.1	4,381	22.8	4,419	23.7	2,959	30.8

Note: Comprehensive income For the nine months ended March 31, 2026: ¥3,047 million [3.5%]
 For the nine months ended March 31, 2025: ¥2,944 million [29.5%]

	Basic earnings per share		Diluted earnings per share	
	Yen		Yen	
Nine months ended				
March 31, 2026	72.47		-	
March 31, 2025	70.27		-	

Note: "Quarterly net income per share adjusted for potential shares" is not included because there are no potential shares.

(2) Consolidated financial position

	Total assets		Net assets		Equity-to-asset ratio	
	Millions of yen		Millions of yen		%	
As of						
March 31, 2026	38,039		30,494		80.2	
June 30, 2025	36,114		28,120		77.9	

Reference: Equity
 As of March 31, 2026: ¥30,494 million
 As of June 30, 2025: ¥28,120 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended June 30, 2025	-	0.00	-	16.00	16.00
Fiscal year ending June 30, 2026	-	0.00	-		
Fiscal year ending June 30, 2026 (Forecast)				18.00	18.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Forecast of consolidated financial results for the fiscal year ending June 30, 2026 (from July 1, 2025 to June 30, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen	
Fiscal year ending June 30, 2026	25,700	10.4	5,430	1.4	5,430	1.0	3,640	0.1	86.42	

Note: Revisions to the earnings forecasts most recently announced: None

* **Notes**

- (1) Significant changes in the scope of consolidation during the period: None
- (2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None
- (3) Changes in accounting policies, changes in accounting estimates, and restatement
- (i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
 - (ii) Changes in accounting policies due to other reasons: None
 - (iii) Changes in accounting estimates: None
 - (iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2026	42,119,980 shares
As of June 30, 2025	42,119,980 shares

(ii) Number of treasury shares at the end of the period

As of March 31, 2026	1,476 shares
As of June 30, 2025	1,476 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Nine months ended March 31, 2026	42,118,504 shares
Nine months ended March 31, 2025	42,118,614 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Proper use of earnings forecasts, and other special matters

(Cautions on forward-looking statements, etc.)

The forward-looking statements, including forecasts of financial results, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable. However, the Company makes no guarantee that these forecasts will be achieved. Actual financial results, etc. may differ substantially due to various factors. For information on the assumptions on which earnings forecasts are based and precautions for using earnings forecasts, please refer to "1. Qualitative Information on Financial Results for the this quarter (3) Explanation of Forward-Looking Information such as Consolidated Earnings Forecasts."

(How to obtain supplementary explanatory materials for financial results)

Supplementary financial results materials will be disclosed on TDnet on the same day and will be posted on the Company's website.

Quarterly consolidated balance sheet

(Thousands of yen)

	As of June 30, 2025	As of March 31, 2026
Assets		
Current assets		
Cash and deposits	14,919,028	13,266,713
Notes and accounts receivable – trade	3,575,127	3,810,083
Electronically recorded monetary claims – operating	4,546,823	4,117,855
Securities	-	281,281
Merchandise and finished goods	2,124,094	2,773,864
Work in process	540,924	480,708
Raw materials and supplies	599,763	651,282
Other	221,905	270,864
Total current assets	26,527,666	25,652,652
Non-current assets		
Property, plant and equipment		
Buildings and structures	5,654,060	5,749,649
Accumulated depreciation	(2,748,896)	(2,908,204)
Buildings and structures, net	2,905,164	2,841,445
Machinery, equipment and vehicles	3,870,459	3,968,283
Accumulated depreciation	(2,958,177)	(3,154,854)
Machinery, equipment and vehicles, net	912,281	813,428
Tools, furniture and fixtures	1,530,744	1,573,496
Accumulated depreciation	(1,200,143)	(1,279,802)
Tools, furniture and fixtures, net	330,600	293,694
Land	1,807,189	1,806,426
Construction in progress	3,240,308	4,716,379
Total property, plant and equipment	9,195,544	10,471,373
Intangible assets		
Other	8,661	7,586
Total intangible assets	8,661	7,586
Investments and other assets		
Investment securities	89,928	1,664,133
Deferred tax assets	263,690	220,361
Retirement benefit asset	17,490	8,724
Other	11,776	14,757
Total investments and other assets	382,886	1,907,977
Total non-current assets	9,587,091	12,386,936
Total assets	36,114,758	38,039,589

	As of June 30, 2025	As of March 31, 2026
Liabilities		
Current liabilities		
Notes and accounts payable – trade	1,567,463	1,485,146
Electronically recorded obligations – operating	448,935	203,148
Short-term borrowings	860,000	2,080,280
Accounts payable – other	361,305	784,811
Accounts payable – facilities	1,277,390	204,798
Current portion of long-term borrowings	349,904	299,804
Income taxes payable	1,039,296	606,948
Provision for bonuses	47,964	95,140
Other	411,420	324,373
Total current liabilities	6,363,679	6,084,450
Non-current liabilities		
Long-term borrowings	1,241,480	1,044,628
Deferred tax liabilities	7,192	5,973
Provision for retirement benefits for directors (and other officers)	162,767	165,923
Retirement benefit liability	146,049	162,630
Other	72,925	81,897
Total non-current liabilities	1,630,414	1,461,053
Total liabilities	7,994,094	7,545,503
Net assets		
Shareholders' equity		
Share capital	1,338,752	1,338,752
Capital surplus	1,022,303	1,022,303
Retained earnings	25,733,458	28,111,965
Treasury shares	(484)	(484)
Total shareholders' equity	28,094,029	30,472,536
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	30,798	19,139
Deferred gains or losses on hedges	(4,163)	2,409
Total accumulated other comprehensive income	26,634	21,549
Total net assets	28,120,664	30,494,085
Total liabilities and net assets	36,114,758	38,039,589

Quarterly consolidated statement of income

(Thousands of yen)

	Nine months ended March 31, 2025	Nine months ended March 31, 2026
Net sales	17,620,607	18,334,054
Cost of sales	11,617,913	11,989,645
Gross profit	6,002,693	6,344,409
Selling, general and administrative expenses	1,620,827	1,763,885
Operating profit	4,381,866	4,580,523
Non-operating income		
Interest and dividend income	2,228	7,598
Interest on securities	-	16,730
Foreign exchange gains	17,098	-
Commission income	150	2,469
Compensation income	34,013	923
Subsidy income	-	5,000
Other	5,010	9,741
Total non-operating income	58,500	42,464
Non-operating expenses		
Interest expenses	10,651	13,930
Foreign exchange losses	-	55,007
Other	10,154	2,402
Total non-operating expenses	20,805	71,340
Ordinary profit	4,419,561	4,551,646
Extraordinary income		
Gain on sale of non-current assets	-	3,552
Total extraordinary income	-	3,552
Profit before income taxes	4,419,561	4,555,199
Income taxes – current	1,425,988	1,458,856
Income taxes – deferred	33,841	43,940
Total income taxes	1,459,829	1,502,797
Profit	2,959,731	3,052,402
Profit attributable to owners of parent	2,959,731	3,052,402

Quarterly consolidated statement of comprehensive income

(Thousands of yen)

	Nine months ended March 31, 2025	Nine months ended March 31, 2026
Profit	2,959,731	3,052,402
Other comprehensive income		
Valuation difference on available-for-sale securities	(5,604)	(11,658)
Deferred gains or losses on hedges	(9,129)	6,573
Total other comprehensive income	(14,733)	(5,085)
Comprehensive income	2,944,998	3,047,317
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	2,944,998	3,047,317

(Notes on segment information, etc.)

Segment Information

I. The nine months of the previous fiscal year (July 1, 2024 to March 31, 2025)

1. Information on sales and the amount of profit or loss for each reported segment, as well as information on the breakdown of revenues

(Thousands of yen)

	Reportable segments			Adjustment amount (Note) 1	Quarterly Consolidated Statements of Income (Note) 2
	API Sales Business	Manufacture and Sales of Pharmaceuticals Business	Total		
Sales					
Revenue generated from customer contracts	10,740,119	6,880,487	17,620,607	-	17,620,607
Other Earnings	-	-	-	-	-
Revenues from external customers	10,740,119	6,880,487	17,620,607	-	17,620,607
Transactions with other segments	994,011	-	994,011	(994,011)	-
Total	11,734,131	6,880,487	18,614,619	(994,011)	17,620,607
Segment Profit	2,389,062	1,932,469	4,321,531	60,335	4,381,866

Note: 1. The adjustment amount of 60,335 thousand yen in segment profit is the elimination of inter-segment transactions and company-wide expenses.

2. The total amount of segment profit is in line with operating income in the quarterly consolidated statements of income.

2. Information on impairment losses or goodwill on fixed assets by reporting segment

Not applicable.

II. The nine months of the current fiscal year (July 1, 2025 to March 31, 2026)

1. Information on sales and the amount of profit or loss for each reported segment, as well as information on the breakdown of revenues

(Thousands of yen)

	Reportable segments			Adjustment amount (Note) 1	Quarterly Consolidated Statements of Income (Note) 2
	API Sales Business	Manufacture and Sales of Pharmaceuticals Business	Total		
Sales					
Revenue generated from customer contracts	11,309,549	7,024,505	18,334,054	-	18,334,054
Other Earnings	-	-	-	-	-
Revenues from external customers	11,309,549	7,024,505	18,334,054	-	18,334,054
Transactions with other segments	939,170	-	939,170	(939,170)	-
Total	12,248,720	7,024,505	19,273,225	(939,170)	18,334,054
Segment Profit	2,588,201	1,931,248	4,519,449	61,073	4,580,523

Note: 1. The adjustment amount of 61,073 thousand yen in segment profit is due to the elimination of inter-segment transactions and company-wide expenses.

2. The total amount of segment profit is in line with operating income in the quarterly consolidated statements of income.

2. Information on impairment losses or goodwill on fixed assets by reporting segment

Not applicable.